One of the primary challenges in targeting TBP is its ubiquitous expression and essential role in normal cellular processes. Any therapeutic strategy must be highly specific to cancer cells to minimize collateral damage to healthy tissues. Additionally, the development of small molecules or other agents that can precisely modulate TBP activity without causing extensive side effects is complex and requires further research.